RxDoctor Payments Data

Craig Henry

Psychiatric/Mental Health · Ocoee, FLNPI 1215789714

Payments from drug & device makers

$2,405in general payments, 2019–2025

Across 98 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$779
  • Alkermes, Inc.$294
  • Vanda Pharmaceuticals Inc.$186
  • AbbVie$185
  • Johnson & Johnson$175
  • Corium, LLC$166
  • plus $619 from 11 others

What the payments were for

  • Food & beverage$2,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,405 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$12,486
Medicare patients
38
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$17,528
Oxcarbazepine36$3,819
Duloxetine Hcl85$2,772
Quetiapine Fumarate149$2,658
Divalproex Sodium ErDivalproex Sodium15$2,452
Atomoxetine Hcl16$2,176
Olanzapine34$2,016
Buspirone Hcl97$1,924
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$1,853
Divalproex Sodium15$1,802
Trazodone Hcl186$1,796
Bupropion XlBupropion Hcl91$1,745
Venlafaxine Hcl ErVenlafaxine Hcl97$1,725
Lamotrigine137$1,535
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine41$1,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$185$17,52812 claims
Lilly USA, LLCOlanzapine$19$2,01634 claims
Almatica Pharma LLCSertraline Hcl$32$651101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Ocoee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →